Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-045351
Filing Date
2024-11-14
Accepted
2024-11-14 08:00:43
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1052205
2 ex31-1.htm EX-31.1 21091
3 ex31-2.htm EX-31.2 20860
4 ex32-1.htm EX-32.1 10343
  Complete submission text file 0001493152-24-045351.txt   5322689

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE zvsa-20240930.xsd EX-101.SCH 45434
6 XBRL CALCULATION FILE zvsa-20240930_cal.xml EX-101.CAL 45733
7 XBRL DEFINITION FILE zvsa-20240930_def.xml EX-101.DEF 181882
8 XBRL LABEL FILE zvsa-20240930_lab.xml EX-101.LAB 401577
9 XBRL PRESENTATION FILE zvsa-20240930_pre.xml EX-101.PRE 298880
61 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 787150
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41184 | Film No.: 241457292
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)